The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 97.50
Bid: 95.00
Ask: 100.00
Change: 0.00 (0.00%)
Spread: 5.00 (5.263%)
Open: 96.00
High: 97.50
Low: 96.00
Prev. Close: 96.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Faron Pharmaceuticals raises EUR12 million

Fri, 27th Jan 2023 10:11

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Inspecs Group PLC, up 15% at 108.00 pence, 12-month range 38.50p-400p. The Bath, England-based eyewear company extends rally from Thursday. On Thursday, Inspecs said full-year trading was in line with expectations, despite Covid-19 restrictions in China and Vietnam. The company predicted revenue for 2022 to be USD246.0 million, flat from USD246.5 million in 2021. It said on a constant exchange rate basis, revenue increased by 9.5%. Looking ahead, Inspecs said it has entered 2023 with a good order book, and it hopes to continue to seek operational efficiencies and reduce costs where appropriate.

----------

AIM - LOSERS

----------

Faron Pharmaceuticals Ltd, down 5.9% at 319.80p, 12-month range 155p-395p. The biopharmaceutical company raises EUR12.0 million from a placing of 3.7 million shares at the issue price of EUR3.25. Faron says that with these proceeds and the current level of activity, it has sufficient working capital into the third quarter of 2023. The main reason for the placing is to accelerate and expand the clinical development of the company's main drug candidate, bexmarilimab.

----------

Goldstone Resources Ltd, down 8.3% at 3.53p, 12-month range 3p-10.75p. The Jersey, UK-based gold development company issues GBP2.4 million of convertible loan notes to Blue Gold International Ltd, which are due for redemption on November 30, 2023. The notes may be converted at any time prior to redemption into new ordinary shares of 1p each in the capital of the Goldstone at a conversion price of GBP0.0325 per share. BGL also receives warrants to subscribe for up to 60.0 million shares at a price of GBP0.04 per share, at any time until January 26, 2025.

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
13 Sep 2018 08:36

Faron losses widen following disappointing Traumakine trial

(Sharecast News) - Faron Pharmaceuticals' operating loss doubled in the first half of its trading year following the group's disappointing trial on its Traumakine treatment.

Read more
12 Sep 2018 13:48

Faron Pharmaceuticals Says New Clever-1 Data Shows B Cell Response

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Wednesday that new data from its cell surface receptor Clever-1 showed B cell response control and humoral antibody production.The by

Read more
6 Sep 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 7 September Secure Income REITHalf Year Results Ashmore GroupFull Year Year

Read more
21 Jun 2018 16:31

DIRECTOR DEALINGS: Faron Pharmaceuticals Directors Buy Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy said on Thursday several directors purchased shares over the course of three days from Tuesday to Thursday.On Tuesday, Non-Executive Matti

Read more
14 Jun 2018 11:30

Faron Pharmaceutics Reports Inconsistent Traumakine Biomarker Results

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Thursday said preliminary biomarker data from its Traumakine phase III trial has produced inconsistent results.Faron is testing in a III

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
24 May 2018 16:10

UK Shareholder Meetings Calendar - Next 7 Days

Friday 25 MayHochschild MiningFerrexpoKeywords Mutual (re managed 28 events 29 Stobart Life (re of

Read more
11 May 2018 08:45

Faron Says Traumakine Trial Did Not Produce Expected Results

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Friday that initial review of the Phase III trial for Traumakine drug used for the treatment of lung inflammation did not produce the seen a

Read more
8 May 2018 11:10

WINNERS & LOSERS SUMMARY: Virgin Money Gains On CYBG Takeover Offer

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - up 4.1%. The Irish drugmaker said it has agreed

Read more
8 May 2018 10:17

Faron Pharmaceuticals Shares Dive As Traumakine Fails In Latest Test

LONDON (Alliance News) - Shares in Finnish firm Faron Pharmaceuticals Oy plunged on Tuesday as the company reported "extremely disappointing" results from its flagship Traumakine shares

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
1 May 2018 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 2 May Direct Line Insurance GroupQ1 ResultsConvaTec GroupQ1 GroupHalf

Read more
4 Apr 2018 12:53

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Read more
9 Feb 2017 08:20

Faron Pharmaceuticals makes solid progress with drug programmes

(ShareCast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals updated the market on Thursday, ahead of its full year 2016 audited financial results which its board said will be announced on 29 March. The AIM-traded firm said for its Traumakine project, it expects to obtain the re

Read more
31 Oct 2016 12:44

Faron Pharma granted protection for IFN-beta by Finnish patent office

(ShareCast News) - Faron Pharmaceuticals' patent application to protect the intravenous use of interferon-beta, a cytokine protein, in a novel formulation has been accepted by the Finnish patent office that enables the company to build a global proprietary position for its Traumakine drug. The claim

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.